ReviewPathogens (Basel, Switzerland)2026
Antimicrobial Drug Prophylaxis for Recurrent Ocular Toxoplasmosis.
Review in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ocular toxoplasmosis is a relapsing infectious eye disease that carries an increasing risk of vision loss with each reactivation episode. Antimicrobial drug prophylaxis has been used to reduce the rate of recurrence. This review aims to summarize the current literature regarding expert clinician preferences, as well as the effectiveness and safety of prophylaxis. A literature search was conducted using the PubMed platform of the National Library of Medicine of the National Center for Biotechnology Information and relevant pre-specified search terms. Four professional surveys indicated that approximately three-quarters of experts gave antimicrobial drug prophylaxis for recurrent ocular toxoplasmosis, and that trimethoprim-sulfamethoxazole was the most popular approach. Clinical studies of prophylaxis varied in multiple parameters, including drug, dosing and duration, plus time of follow-up. Considering the four studies with at least 50 participants, the rate of recurrence of ocular toxoplasmosis within 5 years was up to 9.1% of patients taking prophylaxis, and treatment-limiting side effects occurred in up to 7.9% of patients. The available literature demonstrates that antimicrobial drug prophylaxis can reduce the recurrence rate of ocular toxoplasmosis; however, further research on drug dosing and duration of treatment is required to assist decision-making in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.